All In Biotech

Drug Trial Radar · NCT05700591

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset

Last checked: Nov 20, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,552

Actual

Start

Jan 29, 2023

Primary completion

Mar 14, 2024

Study completion Mar 14, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this purpose. RhPro-UK is a specific plasminogen activator. rhPro-UK only acts on occlusive thrombus and has little effect on hemostatic thrombus. In addition, rhPro-UK does not form covalent complexes with protease inhibitors in plasma, so the concentrations of rhpro-UK and protease inhibitors in the blood do not decrease compared with alteplase. Therefore, rhPro-UK therapies have a potential advantage of less systemic bleeding in treated subjects. Data from several previous studies suggest that rhPro-UK is efficacious when used to treat patients with acute myocardial infarction. On April 2, 2011, rhPro-UK injection was approved by the National Medical Products Administration to treat acute myocardial infarction. Since then, rhPro-UK has been widely used to treat myocardial infarction in China. Since 2016, a phase 2 clinical trial was carried to explore the dosing of rhPro-UK in patients with acute ischemic stroke, followed by another study with a sample size of 680 patients to initially validate the efficacy and safety of the proposed dose of 35mg. The results of these studies suggested that rhPro-UK was effective, and there were no safety concerns. To further prove the efficacy and safety of rhPro-UK in patients with acute ischemic stroke, investigators conducted this phase 3 study (PROST-2).

Conditions

  • Acute Ischemic Stroke

Interventions

  • rhPro-UKDrug

    35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes

  • rt-PADrug

    0.9 mg/kg (maximum 90 mg), with 10% administered intravenously as a bolus, followed by 90% infusion within 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with excellent functional outcome at 90 daysTime frame: 90±7 days

Locations

72 sites in 1 country. Site status is shown where the registry gives one.

  • Xuancheng People's Hospital

    Xuancheng, Anhui, China

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Huizhou First Hospital

    Guangdong, Guangdong, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China

  • Handan Central Hospital

    Handan, Hebei, China

  • Hengshui People's Hospital (Harrison International Peace Hospital)

    Hengshui, Hebei, China

  • Hebei General Hospital

    Shijiazhuang, Hebei, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Xingtai People's Hospital

    Xingtai, Hebei, China

  • The First Affiliated Hospital of Hebei North University

    Zhangjiakou, Hebei, China

  • Daqing Oilfield General Hospital

    Daqing, Heilongjiang, China

  • Daqing People's Hospital

    Daqing, Heilongjiang, China

  • Anyang People's Hospital

    Anyang, Henan, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China

  • Nanshi Hospital of Nanyang

    Nanyang, Henan, China

  • Nanyang Second General Hospital

    Nanyang, Henan, China

  • General Hospital of Pingmei Shenma Medical Group

    Pingdingshan, Henan, China

  • Xinxiang Central Hospital

    Xinxiang, Henan, China

  • Zhumadian Central Hospital

    Zhumadian, Henan, China

  • Tongji Hospital affiliated to Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Wuhan Fourth Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Baogang Hospital of Inner Mongolia

    Baotou, Inner Mongolia, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science & Technology

    Baotou, Inner Mongolia, China

  • Keshiketeng Hospital of Traditional Chinese Medicine and Mongolian Medicine

    Chifeng, Inner Mongolia, China

  • The Affiliated Hospital of Chifeng University

    Chifeng, Inner Mongolia, China

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • General Hospital of Xuzhou Coal Mining Group

    Xuzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Jilin Guowen Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Meihekou Central Hospital

    Meihekou, Jilin, China

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.